As shown in Fig. 6E, the alternative splicing rate of p53 that resulted in a lack of the N-terminal TAD domain in tumor tissues was significantly higher than found in adjacent noncancerous tissues, indicating p53 splice was also an influencer for ATF2 mediated GC chemotherapy. The gene discussed is ATF2; the disease is neoplasm.